

## References

### S-11

1. Diakoumakou O, Hatzigeorgiou G, Kolovou G, et al. Severe/extreme hypertriglyceridemia and LDL apheresis treatment: Review of the literature, original findings. *Cholesterol*. 2014;2014:109263. Ipswich, MA.
2. National Comprehensive Cancer Network. *NCCN clinical practice guidelines in oncology: Multiple Myeloma*. Version 1. 2015.
3. Schwartz, J. Clinical applications of therapeutic-apheresis: An evidence based approach. 6th Edition. *Journal of Clinical Apheresis*. 2013;28(3):145-284.
4. Heigl, F. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a) hyperlipoproteinemia with progressive cardiovascular disease. *Clin Res Cardiol Suppl*. 2015;10:8–13.
5. Varga, V. Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia. *Lipids in Health and Disease*. 2016;15:1-7.
6. Winters, J. National heart, lung, and blood institute state of the science symposium in therapeutic apheresis—Therapeutic apheresis in cardiovascular disease. *Journal of Clinical Apheresis*. 2015;30: 183-187.
7. Su Y, Chiu W, Hsu C, Chen J, Ng H. Lower in-hospital mortality with plasma exchange than plasmapheresis in a subgroup analysis of 374 lupus patients. *Biomed Research International*. 2018;1-8.
8. Wang A, Richharia A, Gandra S, et. al. Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. *J Am Heart Assoc*. 2016;5(7).
9. Ranganathan D, John GT. Therapeutic plasma exchange in renal disorders. *Indian J Nephrol*. 2019;29(3):151-159.
10. Harris E, Meiselman H, Moriarty P, et.al. Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis. *Journal of Scleroderma and Related Disorders*. 2018; 3(2):132-152